LOS ANGELES, Dec. 2, 2016 /PRNewswire/ -- CytRx Corporation
(NASDAQ: CYTR), a biopharmaceutical research and development
company specializing in oncology, today announced the appointment
of Earl Warren Brien, M.D., a noted
sarcoma surgeon, industry consultant, and private healthcare
investor, to its Board of Directors.
"Dr. Brien is a healthcare leader with clinical and strategic
experience at the highest level," said Steven A. Kriegsman, CytRx's Chairman and CEO.
"As one of the world's leading orthopedic surgeons, Dr. Brien has
performed thousands of sarcoma-related surgeries over the course of
his career. He brings a wealth of knowledge to CytRx through
his first-hand experience in treating patients with soft tissue
sarcomas coupled with years of providing strategic counsel to both
biotech and medical device companies. On behalf of the entire
Board and management team, I welcome him and look forward to his
contributions as we advance aldoxorubicin toward a New Drug
Application (NDA) filing for the treatment of soft tissue
sarcomas."
Dr. Brien commented, "My background and deep familiarity with
sarcoma, both as a surgeon and a collaborator with treating sarcoma
physicians, enables me to bring a unique, real world perspective to
CytRx and I am delighted to join its Board of Directors and to work
closely with this world-class scientific and entrepreneurial
team. With positive Phase 3 results now in hand, I believe
aldoxorubicin represents a major step forward for sarcoma patients
and I look forward to making contributions that will assist in
bringing this promising new treatment candidate to patients
suffering with this rare, complex and difficult-to-treat
cancer."
Dr. Brien is a board certified orthopedic and sarcoma surgeon
who currently serves as a Professor of Orthopedic Surgery and
Surgical Director of the Sarcoma Service at Cedars-Sinai Medical
Center in Los Angeles,
California. He earned his medical degree from Howard University School of Medicine and completed
fellowships at the Memorial Sloan-Kettering Cancer Center in
Orthopedic Oncology and at the Hospital for Special Surgery at
Cornell University. Over his more than twenty-year career,
Dr. Brien has received numerous research grants, given over 140
scientific presentations, and been published in numerous
peer-reviewed journals and books.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and
development company specializing in oncology. CytRx currently is
focused on the clinical development of aldoxorubicin, its
albumin-binding conjugate of doxorubicin. CytRx is also
expanding its pipeline of oncology candidates at its laboratory
facilities in Freiburg, Germany,
through its LADR™ (Linker Activated Drug Release) technology
platform, a discovery engine designed to leverage CytRx's expertise
in albumin biology and linker technology for the development of a
new class of anti-cancer therapies.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934,
as amended. Such statements involve risks and uncertainties that
could cause actual events or results to differ materially from the
events or results described in the forward-looking statements,
including risks relating to the timing and final results of CytRx's
clinical testing of aldoxorubicin, timing of CytRx's preparation
and submission of an NDA for aldoxorubicin for the treatment of STS
and FDA acceptance and review of any NDA, the risk that CytRx may
be unsuccessful in obtaining FDA approval or, if approval is
obtained, in commercializing aldoxorubicin in the United States or elsewhere, risks related
to CytRx's need for additional capital or strategic partnerships to
fund its ongoing working capital needs and other risks and
uncertainties described in the most recent annual and quarterly
reports filed by CytRx with the Securities and Exchange Commission
and current reports filed since the date of CytRx's most recent
annual report. All forward-looking statements are based upon
information available to CytRx on the date the statements are first
published. CytRx undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Company Contact:
CytRx Corporation
David J. Haen
Vice President, Business Development and Investor Relations
(310) 826-5648, ext. 304
dhaen@cytrx.com
Media Contact:
Argot Partners
Eliza Schleifstein
(917) 763-8106
eliza@argotpartners.com
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/leading-sarcoma-expert-dr-earl-w-brien-joins-cytrx-board-of-directors-300371995.html
SOURCE CytRx Corporation